🟢 Veru is trading 5.6% up today after Oppenheimer reaffirmed Outperform, $24 target

Veru is trading 5.6% up at $2.25 after Oppenheimer reaffirmed its Outperform rating and $24 price target.

• Investing.com linked the reaffirmation to an after-hours gain and renewed confidence ahead of clinical data for enobosarm; the broader market was mixed.
• The Phase 2b PLATEAU study is fully enrolled; Oppenheimer highlighted its interim analysis, with the full topline readout expected in Q4 2027. No current-session volume data was provided.